<scp>CYT</scp>003, a <scp>TLR</scp>9 agonist, in persistent allergic asthma – a randomized placebo‐controlled Phase 2b study
Thomas B. Casale(University of South Florida), M.E. Wechsler(National Jewish Health), Philippe Saudan, Claus Vogelmeier(German Center for Lung Research), Ekkehard Beck(GlaxoSmithKline (Belgium)), Cheryl Lassen, Jeremy Cole, L. Trokan, Jörg Willers, Anya Hammann‐Haenni
Cited by 68
Related Papers
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
|American Journal of Respiratory and Critical Care Medicine|2017|3.2k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
|Journal of Allergy and Clinical Immunology|2011|1.2k